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Abstract
Intraocular cancer is a serious threat to the lives of those that suffer from it. Dosimetry for eye brachytherapy
presents a significant challenge due to the inherently steep dose gradients that are needed to treat such small tumours
in close proximity to sensitive normal structures. This issue is addressed by providing much needed quality assurance
to eye brachytherapy, a novel volumetric dosimetry system, called Panoptes was developed. This study focuses on
the preliminary characterisation and calibration of the system. Using ion beam facilities, the custom, pixelated silicon
detector of Panoptes was shown to have good charge collection uniformity and a well defined sensitive volume. Flat-
field calibration was conducted on the device using a 250kVp orthovoltage beam. Finally, the detector and phantom
were simulated with Monte Carlo in Geant4, to create water equivalent dose correction factors for each pixel across a
range of angles.
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1. Introduction
Although not as prevalent as some tumours, intraoc-
ular cancers present a significant risk to sufferers [1, 4,
5, 7]. Uveal melanoma is the most commonly occurring
of these and can be treated with a number of modalities.
Brachytherapy is the most widely used radiotherapy treat-
ment for posterior uveal melanoma [7]. It involves suturing
a radioactive source, in the form of a small dish shaped
device called a plaque, directly over the tumour for the
treatment period. Once this duration has expired, it is
removed again. Typical radionuclides used include 103Pd
or 125I as small rice-like seeds that fit into an insert or
106Ru as a uniform coating. The system presented in this
study focuses on 125I plaques, though limitations in the
measurement of other radioisotopes are not yet apparent.
Despite improvements over the years, uncertainties and
limitations still remain in eye brachytherapy including:
loss of vision and other iatrogenic side effects; inability
to treat large tumours; and failure to eliminate the threat
of tumour. Due to the presence of surrounding vital struc-
tures and the small tumour sizes involved, averaging around
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12mm diameter by 6mm thick, dose gradients must be very
steep and are innately difficult to measure.
Currently, no treatment planning system (TPS) is rec-
ommended by either the American Association of Physi-
cists in Medicine (AAPM) or American Brachytherapy So-
ciety (ABS) as a primary dose calculation tool because
none are certified by either the Food and Drug Authorities
(FDA) or Conformité Européenne ( ). The Task Group
43U1 report formalism[6] is used as the industry standard
for dose calculation but assumes infinite water surrounds
and cannot account for material heterogeneities. The ex-
tensive TG-129 Report[2] provides an excellent summary
and recommendations of such issues regarding the current
status of dosimetry for eye plaques. From this, it is sug-
gested that treatment planning can be improved with a
quality assurance system that offers fast, direct dose ver-
ification of eye plaques that: measures the dose close to
the plaque surface; has fast 3D dose mapping; can dis-
play dose near critical structures and; accounts for dose
in many heterogeneous materials thus acting to comple-
ment current TPSs. This study details a system, called
the Panoptes, which provides at method of physically
measuring dose distributions in eye plaques.

















Figure 1: Volumetric dosimetry concept based on superimposing

















Figure 2: Single planar measurements (top) are made at multiple
plaque-detector angles using the Panoptes and superposed to create
a dose volume (bottom).
2. Methods and Materials
Volumetric dosimetry for eye brachytherapy can be
achieved through the super-positioning of multiple planar
dose measurements. This study has lead to the develop-
ment of a volumetric dosimeter which operates by rotat-
ing the plaque, using a stepper motor, about the axis of a
24mm wide semicircular detector, see Figure 1. The detec-
tor shape allows for dose measurement from less than 1mm
from the inner surface of the plaque to the centre of the
eye. This gives good dosimetric coverage of the volume of
the eye surrounding the tumour from which other points
of interest can be extrapolated. Each measurement of the
detector produces a planar semicircular dose map which
can then be reconstructed, through the superposition of
multiple angles, into a single hemispherical dose volume,
such as the example shown in Figure 2.
Following the success of early results with the Medipix
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Figure 3: Photograph of detector mounted on readout board and
bonded to two HERMES4[3], mixed-signal front-end ASICs.
detectors[8, 9], this study has developed the Panoptes,
the pixelated, automated nuclear ophthalmic plaque treat-
ment evaluation system. It features a custom designed and
in-house fabricated detector that consists of an array of 64
silicon p-i-n diodes on a single semicircular cut 300 µm
wafer, aimed at providing dosimetry close to the plaque
surface.
The detector was wire bonded to two HERMES4[3],
low noise, mixed-signal front-end application specific in-
tegrated circuits (ASICs) with 24-bit counters and three
separate energy windows. The ASIC was interfaced to a
graphical user interface for readout via a field-programmable
gate array (FPGA). Figure 3 shows the detector with the
two HERMES ASICs bonded below.
In order to use the device for dosimetry, it must first
be characterised and calibrated. Characterisation was car-
ried out, in part, using ion-beam induced charge collec-
tion (IBICC) at the ANTARES Accelerator at ANSTOd.
During this process, ions of 5.5MeV helium and 11.75MeV
beryllium were focused to approximately one micrometer
and raster scanned across the surface of the detector. The
collected charge was readout using an AMPTEK A250
preamplifier where median energy maps and spectra were
subsequently produced. A number of measurements were
taken adjusting several variables including; bias voltage,
scan size, ion type, gain and connected pixel. The data
were calibrated using a series known pulse inputs.
Preliminary detector calibration was conducted using
two methods: flat-field γ-ray and Monte Carlo simulation.
Flat-field calibration of two detector samples was carried
out at the ICCCc, using a Gulmay D3300, orthovoltage
machine. The sample, without any phantom, was placed
at a distance of three meters from the source in a free air
environment. The HERMES4 was configured with a peak-
ing time of 0.5µs, gain of 0.75V/fC and energy thresholds
set above background noise. The detector was fully de-
pleted at a reverse bias voltage of 50V (based on IBICC
results). Using an energy of 250kVp, 100 acquisitions of
0.1s were taken and integrated for a total time of 10s.
These values were then normalised against the maximum
2
value to produce the calibration factors for each pixel.
Energy correction was calculated using Geant4 version
9.5 patch 01 with Livermore low energy physics models
for Monte Carlo simulation. This involved determining
the silicon to water dose ratio coefficients for each pixel
in the silicon detector averaged over 360◦. The simulation
included modelling the full Panoptes detector, with sen-
sitive volumes corresponding to the pixels placed inside
a poly(methyl methacrylate) (PMMA) eye phantom. A
15mm ROPES eye plaque containing ten Oncura model
6711 125I seeds was located at the apex of the eye phan-
tom. Dose was measured in two eye phantom configura-
tions; one with the semicircular silicon pixelated detector
sandwiched between two PMMA hemispheres in air; and
the other with the silicon, PMMA and air, all replaced
by water. These configurations were used to represent the
phantom apparatus and treatment conditions for calcula-
tion of the silicon to water dose ratio coefficients.
The angular response of each pixel was measured by
varying the plaque axial rotation from 0◦ to 180◦ in 15◦
increments. Due to the symmetry of the model, full the
360◦ could be extrapolated. These factors were then av-
eraged and compared to determine the per average pixel
dose correction factors and their deviations.
3. Results and Discussion
The TG-43U1 method of calculating dose has been
shown to be significantly different from physical measure-
ment and simulation, as summaries in The Task Group
129 Report[2]. The differences have were shown to be up
to 30% off axis and could be accounted for with the imple-
mentation of a dosimetry system such as the Panoptes,
improving the accuracy of dose treatment planning.
In preparation of the Panoptes detector for absolute
dosimetry its pixel volumes was examined in a flat-field,
as described above, and correction factors were determined
for sensitivity and energy response.
3.1. IBICC
The median energy maps and the corresponding en-
ergy spectrum for a single, large pixel (#59, located most
bottom-right of detector, see Figure 1) are displayed in
Figures 4 and 5, respectively. For this measurement the
5.5MeV He2+ ion was used with a 50V bias and a scan
magnification of 6. The energy map shows uniform charge
collection across the detector surface and a well defined
sensitive volume. The definition of this sensitive volume
is critical for accurate, relative dosimetry. Similar results
were observed in other pixels measured, both small and
large in size.
Charge sharing between pixels was tested by comparing
floating to biased pixel neighbours and showed there was
no significant difference. This is important in accurate
dosimetry to ensure that dose is correctly mapped to its
corresponding area.
 



























Figure 4: Ion-beam induced charge collection median energy map
(#59, most bottom-right of large pixels) showing well defined sen-













Figure 5: Energy spectrum corresponding to the median energy map
in Figure 4, showing full charge collection at incident particle energy.
A comparison of the spectra taken from several median
energy maps showed that full charge collection occurs at
the incident particle energy for a bias voltage of 50V. This
voltage was thus selected as the operational voltage of the
detector. A small shoulder to the left of this peak is con-
tributed by the Al metallisation surrounding the perimeter
of the p+ implanted region (visible in Figure 4) and will
have negligible effect on 125I and 106Ru dosimetry.
3.2. Flat-field calibration
The flat-field calibration factors for the individual pix-
els are displayed in Figure 6. There are two distinct groups
depicted, showing the small pixels at the top and the large
pixels at the bottom, with mean values of 8.40(σ = 0.63)
and 1.10(σ = 0.06) relative to maximum pixel response,
respectively. The small pixels have an equivalently higher
calibration factor than the large pixels (∼ 7.5 times) due
to the lower amount of energy they receive as a result
of having a smaller sensitive volume. Good uniformity
across large pixels was observed, while small pixels showed
a greater deviation, due, in part, to great variations in
track length. The longer tracks contribute a higher capac-





















Figure 6: Flat-field calibration factors of all pixels, showing the effect
of pixel geometry on measurable sensitivity.
leads to reduced response. During measurements, the re-
sponse from each Panoptes detector will be divided by
the flat-field calibration factors to normalise the responses
in conjunction with the Monte Carlo generated energy cor-
rection factors.
3.3. Monte Carlo Energy Correction
The water equivalent dose correction factors calculated
for each pixel as the average of all angles are displayed
in Figure 7. The error bars for each data point repre-
sent one standard deviation of the discrepancy across all
angles. With these correction factors applied, simulated
Panoptes data, calculated as silicon pixels in PMMA
and converted to dose in water per unit area, predicted
treatment dose rates to within 2% for most pixels and
up to 9.5% for pixels furthest from the plaque. Whilst
these values predominantly lie within current treatment
uncertainties, further improvement could be achieved by
implementing angle specific correction factors instead of
averaged across all angles, the accuracy of which would
need to be measured experimentally. The pixels with the
lowest deviation across the range of angles are those lo-
cated in the top-central region of the detector, directly
over the most likely tumour location, providing excellent
intratumour accuracy. Angular dependence must be thor-
oughly considered to ensure that the system responds as
expected, especially when dealing with customised plaque
designs.
The Monte Carlo correction factors obtained for each
pixel will be used in conjunction with the above flat-field
calibration to create individual correction factors for each
pixel in Panoptes measurements.
4. Conclusion
The steep dose gradients that must be used for treat-
ing intraocular tumours cause great challenges in dosime-
try measurements for the treatment. Until a TPS is ap-
























Figure 7: Simulated Si : H2O dose ratio correction factors for each
pixel averaged across all angles. Error bars indicate one standard
deviation.
mary dose calculation tool, though it does not account for
material heterogeneities. The TG-129 Report summarises
several studies showing that the presence of the plaque
has a significant effect of dose in comparison to homoge-
nous water[2] and should be considered in dose calcula-
tions. The current state of eye brachytherapy treatment
verification is lagging behind technological feasibility.
Characterisation of the novel pixelated, semicircular
detector using ion beam facilities has shown that the sen-
sitive volume of the detector is well defined, charge collec-
tion is uniform and charge sharing between pixels is not
present. These qualities are important for accurate, rel-
ative dosimetry. The detector’s operational voltage was
determined (50V) through observing the spectra for full
charge collection.
Calibration of the detector accounting for individual
pixel sensitivity was conducted using flat-field γ-rays from
an 250kVp orthovoltage machine. In addition to this, Monte
Carlo simulations using Geant4 were used to calculate dose
to water equivalence correction factors for each pixel, av-
eraged for all angles from 0◦ to 360◦ in 15◦ increments.
The energy correction factors fall to within 2% for most
pixels while the maximum deviation across all pixels and
angles is 9.5%.
Providing a reliable volumetric dosimetry tool, such as
Panoptes, for pretreatment dose verification would be an
excellent complement to current TPSs for eye brachyther-
apy. Such a tool would not only give medical physicists
more confidence in their treatments, but also allow them
to develop patient specific, customised plaques with the
increasing popularity of 3D printing.
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